Vertex Pharms Stock
StockStockPrice
Frequently asked questions
What is Vertex Pharms's market capitalization?
What is the Earnings Per Share (EPS) for Vertex Pharms?
What are the analyst ratings and target price for Vertex Pharms's stock?
What is Vertex Pharms's revenue over the trailing twelve months?
What is the EBITDA for Vertex Pharms?
What is the free cash flow of Vertex Pharms?
What is the 5-year beta of Vertex Pharms's stock?
How many employees does Vertex Pharms have, and what sector and industry does it belong to?
What is the free float of Vertex Pharms's shares?
Financials
Market Cap
$122.62B5Y beta
0.40EPS (TTM)
-$2.024Free Float
257.88MRevenue (TTM)
$10.34BEBITDA (TTM)
$4.46BFree Cashflow (TTM)
-$1.43BPricing
Analyst Ratings
The price target is $468.58 and the stock is covered by 29 analysts.
Buy
20
Hold
6
Sell
3
Information
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.
5,400
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker